MX2009005413A - Formas cristalinas del acido zoledronico. - Google Patents
Formas cristalinas del acido zoledronico.Info
- Publication number
- MX2009005413A MX2009005413A MX2009005413A MX2009005413A MX2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A
- Authority
- MX
- Mexico
- Prior art keywords
- zoledronic acid
- crystalline forms
- crystalline form
- crystalline
- free acid
- Prior art date
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004276 zoledronic acid Drugs 0.000 title abstract 6
- 239000002253 acid Substances 0.000 abstract 4
- 150000004682 monohydrates Chemical class 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a nuevas formas cristalinas de sales de ácido zoledrónico de baja solubilidad en agua, al proceso para la preparación de estas formas cristalinas, a composiciones que contienen estas formas cristalinas, y al uso de estas formas cristalinas en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos. La invención se refiere a la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, al proceso para la preparación de la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, a composiciones que contienen la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, y al uso de la forma cristalina del monohidrato de ácido libre del ácido zoledrónico en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06124850A EP1925621A1 (en) | 2006-11-27 | 2006-11-27 | Crystalline forms of zoledronic acid |
| PCT/EP2007/010255 WO2008064849A1 (en) | 2006-11-27 | 2007-11-26 | Crystalline forms of zoledronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009005413A true MX2009005413A (es) | 2009-06-01 |
Family
ID=37909616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009005413A MX2009005413A (es) | 2006-11-27 | 2007-11-26 | Formas cristalinas del acido zoledronico. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100056481A1 (es) |
| EP (2) | EP1925621A1 (es) |
| JP (1) | JP2010510970A (es) |
| KR (1) | KR20090083407A (es) |
| CN (1) | CN101535323A (es) |
| AR (1) | AR063923A1 (es) |
| AU (1) | AU2007324833A1 (es) |
| BR (1) | BRPI0719567A2 (es) |
| CA (1) | CA2670638A1 (es) |
| CL (1) | CL2007003389A1 (es) |
| MX (1) | MX2009005413A (es) |
| PE (1) | PE20081391A1 (es) |
| RU (1) | RU2009123936A (es) |
| TW (1) | TW200829598A (es) |
| WO (1) | WO2008064849A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2407746C2 (ru) * | 2008-09-29 | 2010-12-27 | ЗАО "Фарм-Синтез" | Радиофармацевтическое средство для диагностики и лечения (терапии) костных поражений скелета и способ его получения |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| EP3158867B1 (en) | 2009-07-31 | 2018-12-12 | Grünenthal GmbH | A method for increasing the aqueous solubility of a bisphosphonic acid or a bisphosphonate |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| DK2459176T3 (en) | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| CN102639137A (zh) * | 2009-09-01 | 2012-08-15 | 杜克大学 | 双膦酸类组合物及其治疗心力衰竭的方法 |
| JP2013525294A (ja) | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | インプラント骨結合を改善するための方法および組成物 |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| JP6492321B2 (ja) * | 2015-03-23 | 2019-04-03 | 株式会社大阪合成有機化学研究所 | ［１−ヒドロキシ−２−（イミダゾ［１，２−ａ］ピリジン−３−イル）エチリデン］ビスホスホン酸一水和物の製造方法 |
| EP3455229B1 (en) | 2016-05-13 | 2021-03-24 | Thar Pharma LLC | Novel crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| CN106749405B (zh) * | 2016-12-29 | 2019-07-16 | 江苏省原子医学研究所 | 一种咪唑杂环类双膦酸化合物及其制备方法、应用 |
| US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
| CN110551152A (zh) * | 2018-05-31 | 2019-12-10 | 四川科伦药物研究院有限公司 | 唑来膦酸一水合物及无水物晶型制备方法 |
| CA3136495A1 (en) * | 2019-04-11 | 2020-10-15 | Xiamen Innovax Biotech Co., Ltd. | Preparation of zinc zoledronate micro/nanoparticle adjuvant and use thereof as vaccine adjuvant |
| TW202136188A (zh) * | 2019-12-13 | 2021-10-01 | 美商睿治尼斯公司 | 金屬鹽及其用途 |
| CN112778365A (zh) * | 2020-12-30 | 2021-05-11 | 华南理工大学 | 一种唑来膦酸钙配合物及其制备方法 |
| CN112724174A (zh) * | 2020-12-30 | 2021-04-30 | 华南理工大学 | 一种薄片状双膦酸钙配合物及其制备方法 |
| CN112646193A (zh) * | 2020-12-30 | 2021-04-13 | 华南理工大学 | 一种块状双膦酸钙配合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4244422A1 (de) * | 1992-12-29 | 1994-06-30 | Boehringer Mannheim Gmbh | Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel |
| US20040097468A1 (en) * | 2002-11-20 | 2004-05-20 | Wimalawansa Sunil J. | Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment |
| ATE425170T1 (de) * | 2003-07-03 | 2009-03-15 | Teva Pharma | Kristallformen der zoledronsäure und deren natrioumsalze, amorphes natriumzoledronat und verfahren zu deren herstellung |
| US20060178439A1 (en) * | 2005-01-04 | 2006-08-10 | Mohakhud Pradeep K | Crystalline form of zoledronic acid |
| AR054673A1 (es) * | 2005-07-28 | 2007-07-11 | Gador Sa | Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende |
| EP1931326A4 (en) * | 2005-09-12 | 2009-12-16 | Reddys Lab Ltd Dr | CRYSTALLINE TRIHYDRATE OF ZOLEDONIC ACID |
| WO2007125521A2 (en) * | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
-
2006
- 2006-11-27 EP EP06124850A patent/EP1925621A1/en not_active Ceased
-
2007
- 2007-11-23 PE PE2007001630A patent/PE20081391A1/es not_active Application Discontinuation
- 2007-11-23 AR ARP070105215A patent/AR063923A1/es unknown
- 2007-11-26 BR BRPI0719567-2A patent/BRPI0719567A2/pt not_active Application Discontinuation
- 2007-11-26 CL CL200703389A patent/CL2007003389A1/es unknown
- 2007-11-26 WO PCT/EP2007/010255 patent/WO2008064849A1/en active Application Filing
- 2007-11-26 CA CA002670638A patent/CA2670638A1/en not_active Abandoned
- 2007-11-26 TW TW096144824A patent/TW200829598A/zh unknown
- 2007-11-26 EP EP07846821A patent/EP2089404A1/en not_active Withdrawn
- 2007-11-26 AU AU2007324833A patent/AU2007324833A1/en not_active Abandoned
- 2007-11-26 JP JP2009537559A patent/JP2010510970A/ja active Pending
- 2007-11-26 RU RU2009123936/04A patent/RU2009123936A/ru not_active Application Discontinuation
- 2007-11-26 US US12/515,742 patent/US20100056481A1/en not_active Abandoned
- 2007-11-26 CN CNA2007800419850A patent/CN101535323A/zh active Pending
- 2007-11-26 KR KR1020097010727A patent/KR20090083407A/ko not_active Application Discontinuation
- 2007-11-26 MX MX2009005413A patent/MX2009005413A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101535323A (zh) | 2009-09-16 |
| WO2008064849A1 (en) | 2008-06-05 |
| BRPI0719567A2 (pt) | 2013-12-10 |
| PE20081391A1 (es) | 2008-11-14 |
| EP2089404A1 (en) | 2009-08-19 |
| US20100056481A1 (en) | 2010-03-04 |
| TW200829598A (en) | 2008-07-16 |
| EP1925621A1 (en) | 2008-05-28 |
| RU2009123936A (ru) | 2011-01-10 |
| CA2670638A1 (en) | 2008-06-05 |
| CL2007003389A1 (es) | 2008-06-27 |
| AR063923A1 (es) | 2009-02-25 |
| AU2007324833A1 (en) | 2008-06-05 |
| KR20090083407A (ko) | 2009-08-03 |
| JP2010510970A (ja) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009005413A (es) | Formas cristalinas del acido zoledronico. | |
| MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| TW200606162A (en) | Pyrazolopyridine derivatives | |
| EA201101243A1 (ru) | 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
| MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MX2009012066A (es) | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. | |
| PH12012502569A1 (en) | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts | |
| WO2010011772A3 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
| TW200833663A (en) | Therapeutic agents | |
| EP2418945A4 (en) | Mineral salt-sulfuric acid compositions and methods for their use | |
| TNSN07165A1 (en) | Organic compounds | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX2009007265A (es) | Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion. | |
| WO2010036567A3 (en) | Harmine compounds for promoting bone growth | |
| WO2010022201A3 (en) | Folinic acid derivatives for promoting bone growth | |
| MX2011008074A (es) | Macrolido anti-inflamatorio. | |
| GB0609897D0 (en) | Compounds | |
| SMT201300112B (it) | Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene | |
| MY148254A (en) | Tartrate derivatives for use as coagulation factor ixa inhibitors | |
| MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| TW200833708A (en) | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | |
| MY160005A (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |